stoxline Quote Chart Rank Option Currency Glossary
  
Hologic, Inc. (HOLX)
73.27  -0.53 (-0.72%)    05-28 15:14
Open: 73.58
High: 73.86
Volume: 602,478
  
Pre. Close: 73.8
Low: 72.88
Market Cap: 17,100(M)
Technical analysis
2024-05-28 2:51:53 PM
Short term     
Mid term     
Targets 6-month :  90.08 1-year :  93.14
Resists First :  77.12 Second :  79.75
Pivot price 74.95
Supports First :  72.87 Second :  60.63
MAs MA(5) :  74.1 MA(20) :  75.23
MA(100) :  75.07 MA(250) :  74.22
MACD MACD :  -0.6 Signal :  -0.5
%K %D K(14,3) :  7.6 D(3) :  7.7
RSI RSI(14): 33.5
52-week High :  82.44 Low :  64.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HOLX ] has closed below the lower bollinger band by 2.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 74.36 - 74.79 74.79 - 75.24
Low: 72.52 - 72.99 72.99 - 73.51
Close: 72.91 - 73.73 73.73 - 74.62
Company Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Headline News

Mon, 27 May 2024
Here's Why You Should Retain Hologic (HOLX) Stock for Now - Yahoo Movies UK

Mon, 27 May 2024
Orion Portfolio Solutions LLC Lowers Stock Position in Hologic, Inc. (NASDAQ:HOLX) - Defense World

Mon, 27 May 2024
3 Reasons Why Growth Investors Shouldn't Overlook Hologic (HOLX) - Yahoo Singapore News

Mon, 27 May 2024
Brokers Offer Predictions for Hologic, Inc.'s Q2 2025 Earnings (NASDAQ:HOLX) - Defense World

Sun, 26 May 2024
Beacon Pointe Advisors LLC Reduces Stake in Hologic, Inc. (NASDAQ:HOLX) - Defense World

Fri, 24 May 2024
Hologic Inc. stock outperforms competitors despite losses on the day - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 233 (M)
Shares Float 230 (M)
Held by Insiders 0.7 (%)
Held by Institutions 99.4 (%)
Shares Short 4,580 (K)
Shares Short P.Month 4,440 (K)
Stock Financials
EPS 1.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 20.76
Profit Margin 11.7 %
Operating Margin 23.8 %
Return on Assets (ttm) 6.2 %
Return on Equity (ttm) 9.1 %
Qtrly Rev. Growth -0.9 %
Gross Profit (p.s.) 0
Sales Per Share 16.96
EBITDA (p.s.) 5.22
Qtrly Earnings Growth -17.3 %
Operating Cash Flow 1,100 (M)
Levered Free Cash Flow 737 (M)
Stock Valuations
PE Ratio 37.81
PEG Ratio 2.5
Price to Book value 3.53
Price to Sales 4.32
Price to Cash Flow 15.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android